Tatva Chintan Pharma Chem Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Tatva Chintan Pharma Chem Ltd filed with BSE on 19 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Tatva Chintan reported Q4 FY26 operating revenue of INR1,341 million, up 24% year-on-year, and EBITDA of INR281 million, up 214% year-on-year, with management attributing the improvement to better product mix and operating leverage. Management described progress across segments including Electrolyte Salts, Structure Directing Agents, Pharma and Agro Intermediates, and a semiconductor chemicals initiative, along with plans for a new greenfield project at Jolva. Management also discussed the impact of rising raw material costs linked to the geopolitical situation and steps taken to pass these costs to customers.
2 statements from this call are not shown because their supporting quotes could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Operating revenue: INR1,341 million (Q4 FY26)
p. 3
“For Q4 FY26, the company reported operating revenue of INR1,341 million, reflecting a strong growth of 24% year-on-year and 2% quarter-on-quarter.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
EBITDA: INR281 million (Q4 FY26)
p. 3
“EBITDA for the quarter stood at INR281 million, marking a significant increase of 214% compared to the same period last year and a 10% improvement sequentially.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Phase Transfer Catalyst revenue: INR311 million (Q4 FY26)
p. 3
“Phase Transfer Catalyst , it recorded revenue of INR311 million, registering an 11% sequential growth through -- though the revenue was lower by 20% on a year-on-year basis.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Electrolyte Salts revenue: INR131 million (Q4 FY26)
p. 3
“Electrolyte Salts delivered a strong performance with revenue of INR131 million, reflecting an exceptional growth of 865% quarter-on-quarter and 1,378% year-on-year.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Pharma and Agro Intermediates and Specialty Chemicals revenue: INR358 million (Q4 FY26)
p. 3
“Pharma and Agro Intermediates and Specialty Chemicals generated revenue of INR358 million, representing a 10% increase year-on-year and despite a 24% decline sequentially.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Structured directing agents revenue: INR525 million (Q4 FY26)
p. 3
“Structured directing agents reported revenue of INR525 million, witnessing a marginal decline of 2% quarter-on-quarter, while achieving a robust 52% growth compared to the corresponding quarter last year.”
Ajesh Pillai, page 3 of the filed PDF · View the filing
Full year revenue: in excess of INR500 crores (FY26)
p. 4
“I would utilize this opportunity to congratulate all the stakeholders on achieving revenue in excess of INR500 crores in recently concluded financial year.”
Ajesh Pillai, page 4 of the filed PDF · View the filing
Peak utilization of current capacity: 80% to 85%
p. 7
“Around 85% -- 80% to 85% range.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Annualized effective tax rate: around 26% (FY26)
p. 12
“Otherwise, if you look at the annual figure, it would be somewhere around 26%.”
Ajesh Pillai, page 12 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — around 25% · FY27
stated firmly by Ajesh Pillai
p. 6
“We have already maintained that we will be growing the revenue by around 25% and EBITDA should be in the range of somewhere around 20% to 22% on a very realistic basis. So, we will stick to that.”
Ajesh Pillai, page 6 of the filed PDF · View the filing
EBITDA margin — 20% to 22% · FY27
stated firmly by Chintan Shah
p. 10
“So there also, we stay with 20% to 22%.”
Chintan Shah, page 10 of the filed PDF · View the filing
Electrolyte Salts contribution to revenue — 8% to 10% · FY27
stated firmly by Ajesh Pillai
p. 7
“Around 8% to 10% that we had already informed in last earning call, and we are still going by that.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Jolva project commercial production — January 2028
stated conditionally by Ajesh Pillai
p. 7
“So roughly around in January 2028. I mean, first couple of months of 2028, we would be commercializing Jolva plant.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Current Dahej facility revenue potential — INR850 crores to INR900 crores
stated firmly by Ajesh Pillai
p. 7
“From the current facility, it would be somewhere around INR850 crores to INR900 crores of revenue.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Jolva Phase 1 revenue potential — INR400 crores to INR500 crores
stated as an aspiration by Chintan Shah
p. 7
“For Phase 1, we estimate the revenue potential in the range of INR400 crores to INR500 crores.”
Chintan Shah, page 7 of the filed PDF · View the filing
Electrolyte Salts revenue growth — 4x of this revenue · FY27
stated firmly by Chintan Shah
p. 8
“It may not be apple-to-apply every quarter, but on a yearly basis, you can say it would be 4x of this revenue is what we can project correctly.”
Chintan Shah, page 8 of the filed PDF · View the filing
Hybrid battery application online — November or December of this calendar year
stated firmly by Chintan Shah
p. 8
“Second application of hybrid battery will go online by somewhere in the phase of November or December of this calendar year.”
Chintan Shah, page 8 of the filed PDF · View the filing
Pharma segment revenue — INR70 crores to INR75 crores · FY27
stated firmly by Chintan Shah
p. 9
“On the upper side, we should see a revenue in the range of about, I believe, somewhere close to INR70 crores, INR75 crores in this financial year.”
Chintan Shah, page 9 of the filed PDF · View the filing
SDA segment growth — INR250 crores to INR300 crores · FY27
stated firmly by Chintan Shah
p. 9
“We expect to grow at least by 20% in this current financial year. We should reach anywhere number between INR250 crores to INR300 crores this year.”
Chintan Shah, page 9 of the filed PDF · View the filing
Euro 7 order uptick — July or August
stated conditionally by Chintan Shah
p. 9
“So yes, we'll see that uptick probably somewhere around July or August is when we'll start seeing that uptick in the numbers as well.”
Chintan Shah, page 9 of the filed PDF · View the filing
Revenue growth (revised discussion) — 20% to 25% · FY27
stated conditionally by Chintan Shah
p. 10
“So, I would stay a little conservative with a prediction of 20% to 25%, give or take.”
Chintan Shah, page 10 of the filed PDF · View the filing
Total capex — INR100 crores in FY27, INR175 crores in FY28 · FY27-FY28
stated firmly by Chintan Shah
p. 12
“Current financial year INR100 crores and INR175 crores in the next financial year.”
Chintan Shah, page 12 of the filed PDF · View the filing
Semiconductor chemicals commercialization — end of 2028, early 2029
stated as an aspiration by Chintan Shah
p. 15
“Actual commercialization, we expect by end of 2028, early 2029 when the product will be really used into chip manufacturing.”
Chintan Shah, page 15 of the filed PDF · View the filing
Full potential of Dahej facility — FY28
stated firmly by Chintan Shah
p. 11
“Next -- so not this current financial year, but next financial year.”
Chintan Shah, page 11 of the filed PDF · View the filing
Jolva groundbreaking — within next 60 days
stated firmly by Chintan Shah
p. 11
“And then I think by -- within next 60 days, we should be breaking the ground for this facility.”
Chintan Shah, page 11 of the filed PDF · View the filing
Jolva investment — INR250 crores to INR270 crores
stated firmly by Chintan Shah
p. 11
“Roughly in that range, yes.”
Chintan Shah, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management reiterated prior guidance of around 25% revenue growth and 20-22% EBITDA margin.
Answered by Ajesh Pillai
Asked by Siddhant Singh: How should we think about FY27 revenue growth and EBITDA margin outlook given Q4 achieved 21% EBITDA margin?
p. 6
“We have already maintained that we will be growing the revenue by around 25% and EBITDA should be in the range of somewhere around 20% to 22% on a very realistic basis.”
Ajesh Pillai, page 6 of the filed PDF · View the filing
Management said guidance is unchanged as customers are gradually absorbing cost increases.
Answered by Ajesh Pillai
Asked by Siddhant Singh: Given geopolitical issues, is the EBITDA guidance being lowered?
p. 7
“We don't intend to change anything on our guidance in that matter.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Management said the project is at planning stage and commercial production is expected around January 2028.
Answered by Ajesh Pillai
Asked by Siddhant Singh: What is the commercial execution timeline for the Jolva project?
p. 7
“We are at the planning stage. We are actually at the planning stage. And after the planning, we would take somewhere around 18 to 20 months.”
Ajesh Pillai, page 7 of the filed PDF · View the filing
Management said growth is sustainable and projected around 4x the annual revenue base, driven by a single application currently, with a second application coming online later in the year.
Answered by Ajesh Pillai
Asked by Sanjesh Jain: Is the sharp jump in Electrolyte Salts this quarter a sustainable run rate for the year?
p. 8
“It's a sustainable growth. Sanjeshji, it will be somewhere around the same point in all the quarters.”
Ajesh Pillai, page 8 of the filed PDF · View the filing
Management explained that carryforward losses meant the company was not entitled to 10AA benefits this year, and heavy capex increased deferred tax, with the annual effective rate closer to 26%.
Answered by Ajesh Pillai
Asked by Sanjesh Jain: Why was the tax rate exceptionally high at 38% this quarter?
p. 12
“The 10AA benefits are not -- we are not entitled to 10AA benefits this year. And plus the capitalization, I mean, the capex has been very heavy.”
Ajesh Pillai, page 12 of the filed PDF · View the filing
Management said customer forecasts are usually precise and that price fluctuations from raw materials have historically been absorbed into new pricing, with demand volatility being the real risk.
Answered by Chintan Shah
Asked by Jay Vaghasia: Is SDA business inherently risky due to lack of confirmed purchase orders and raw material fluctuation?
p. 13
“So that is not at all a risk in this particular part of business. The only risk is in terms of demand when it becomes really volatile.”
Chintan Shah, page 13 of the filed PDF · View the filing
Management said the company is well positioned this time compared to being a late entrant in Euro 6, and expects market share to gradually rise for new opportunities.
Answered by Chintan Shah
Asked by Jay Vaghasia: Could Tatva Chintan gain more market share from Sarchem once Euro 7 kicks in?
p. 14
“But Euro 7, we are very well in time, we have our foot in the door right from beginning.”
Chintan Shah, page 14 of the filed PDF · View the filing
Management explained that the company retains the majority of earnings and distributes only a small portion as dividend to reward shareholders.
Answered by Chintan Shah
Asked by Jay Vaghasia: What is the rationale for paying dividends while short-term borrowings have increased?
p. 14
“Basically, it is that we retain 80% of our earnings post the net profit. We want to distribute nearly about 10% of that profit in terms of dividend.”
Chintan Shah, page 14 of the filed PDF · View the filing
Risks flagged
Rising raw material and fuel costs due to geopolitical conflicts
p. 6
“The current ongoing geopolitical conflicts definitely pose challenges. This leading to rising cost of fuel, packing material.”
Ajesh Pillai, page 6 of the filed PDF · View the filing
Sharp rise in amine raw material prices following the Iran issue
p. 10
“But the prices have gone up by nearly 30%, 40%, so that is a deterrent.”
Chintan Shah, page 10 of the filed PDF · View the filing
Temporary unavailability of amines impacting production days
p. 10
“Somewhere in March, we lost a lot many production days because of unavailability of the amines.”
Chintan Shah, page 10 of the filed PDF · View the filing
Some customers resisting raw material price pass-through, impacting EBITDA
p. 10
“There are certain cases where customers are adamant in terms of allowing us to change the raw material price.”
Chintan Shah, page 10 of the filed PDF · View the filing
Demand volatility as the key risk in the SDA business
p. 13
“The only risk is in terms of demand when it becomes really volatile.”
Chintan Shah, page 13 of the filed PDF · View the filing
Historical demand crash in SDA following post-COVID inventory pile-up
p. 13
“That is what has happened during the past 2 years where demand literally vanished because of massive uptake that happened post COVID, a lot of inventory pile up happened and suddenly the demand crashed because of that.”
Chintan Shah, page 13 of the filed PDF · View the filing
General geopolitical uncertainty potentially affecting customers
p. 9
“There are a lot of uncertainties in terms of the geopolitical issues that are happening. It may not hit us, but it may hit the customer.”
Chintan Shah, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.